Facebook
Twitter
LinkedIn
ForwardNew HCV Therapies | Anthony Albanese, MD
Many patients with chronic HCV are undiagnosed and untreated, and most of these became infected as a result of drug use. Addiction treatment providers need to learn the importance of screening for HCV along with the risks, benefits, and cure rates using the newest available medication treatment regimens
PRICE/PURCHASE -- $50
You must sign in or register register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and click "Add to Cart."
CREDIT
PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 0.5 AMA/PRA Category 1 Credits™ for completing the Review Course.
Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors.
Target Audience
- Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
- Primary care clinicians who want to get a better understanding of addiction and manage patients with addictions in their practice
- Public health officials who want an understanding of the current state of addiction treatment
- Non-physicians who are involved in the treatment of addiction
Learning Objectives
- Understand epidemiology of HCV and progress in treatment over the past 20 years.
- Be able to apply HCV screening techniques to your addiction medicine/psychiatry practice.
- Describe how newly approved Direct Acting Antivirals (DAAs) impact HCV lifecycle.
- Learn about Sustained Viral Response Rates (SVR), risks, limitations ,side effects and benefits of combined therapy DAA regimens.
- Briefly mention non-FDA approved future directions for HCV therapy.
Speaker
Anthony Albanese, MD, Chief, Hepatology Division, VA Northern California Healthcare System, Health Sciences Clinical Professor of Medicine, UC Davis Medical School
Dr. Albanese is on the speakers bureau for Gilead, AbbVie, Genentech, and Merck
Planners
| Sharone Abramowitz, MD | No relevant financial Relationship to disclose |
| Anthony Albanese, MD, FASAM | Speakers bureau for Gilead, AbbVie, Genentech, and Merck |
| Chwen-Yuen (Angie) Chen, MD | No relevant financial Relationship to disclose |
| Helen Py Driscoll, MD | No relevant financial Relationship to disclose |
| Chris Fritsch, MD | No relevant financial Relationship to disclose |
| Murtuza Ghadiali, MD | No relevant financial Relationship to disclose |
| Anna Lembke, MD | No relevant financial Relationship to disclose |
| Claudia Landau, MD | No relevant financial Relationship to disclose |
| Jean Marsters, MD | No relevant financial Relationship to disclose |
| Thomas Meeks, MD | No relevant financial Relationship to disclose |
| David Pating, MD | No relevant financial Relationship to disclose |
| Kenneth Saffier, MD | No relevant financial Relationship to disclose |
| Ingeborg Schafhalter-Zoppoth, MD | No relevant financial Relationship to disclose |
| Tauheed Zaman, MD | No relevant financial Relationship to disclose |
Available Credit
- 0.50 AMA Category 1